Generated by AI
Organogenesis Holdings Inc. Class A Common Stock represents ownership in Organogenesis Holdings Inc., a regenerative medicine company focused on developing, manufacturing, and commercializing products for advanced wound care and surgical and sports medicine. The company’s portfolio includes bioactive and acellular biomaterials designed to support healing across chronic and acute wound applications, as well as surgical biologics used in orthopedic and spine-related settings. Its products are used by healthcare providers across hospitals, clinics, and other care environments that treat patients with complex wounds and tissue repair needs. Organogenesis Holdings Inc. serves a specialized role in the broader healthcare market by supplying biologic and tissue-based solutions aimed at improving clinical care pathways in wound management and regenerative therapies. The company is headquartered in Canton, Massachusetts.
Website85 Dan Road
Canton, MA, 02021
United States
The latest articles about ORGO.
Organogenesis Holdings Inc (ORGO) posted 6% sequential revenue growth and sharp expense reductions while navigating a 70% revenue decline and an extended Amnuvix PDUFA timeline.
Motley Fool Press Release.
Summary of May 13's posts. Generated by AI.
Summary of Apr 7's posts. Generated by AI.
Summary of Nov 19's posts. Generated by AI.
Investors talking about ORGO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.